What happened
Shares of Arrowhead Pharmaceuticals Inc. (ARWR +1.80%), a preclinical-stage biotech developing therapies that silence troublesome genes, jumped after presentations at this year's J.P. Morgan Healthcare Conference. The stock was up 16.1% as of 2:04 p.m. EST on Thursday.
So what
Investors got excited about Arrowhead earlier this week when they noticed Amgen (AMGN 4.67%) highlighted an Arrowhead molecule, AMG-890, as a cornerstone in the big biotech's ongoing expansion into cardiovascular disease.
Image source: Getty Images.
This morning, Arrowhead gave more details that made them smile. According to Arrowhead, Amgen now has an exclusive license to the atherosclerosis candidate formerly known as ARO-LPA, and an option to develop another against an undisclosed target.
Arrowhead receives royalty rights if a candidate succeeds, $35 million in up-front cash and a $21.5 million equity investment. Potential milestone payments could raise the deal's value as high as $673.5 million. All in all, it looks like a terrific deal for preclinical assets discovered with an unproven platform.
Now what
Arrowhead hasn't started human trials with any of its new drug candidates, but it did file clinical-trial applications in New Zealand that could allow it to take the important step with two unlicensed candidates soon. My favorite of the two, ARO-AAT, silences a gene that leads to overexpression and buildup of a misfolded protein in the livers of approximately 100,000 Americans with alpha-1 liver disease.
Arrowhead's candidate knocked levels of the protein down 92% in preclinical studies. Alpha-1 liver disease lacks effective treatments, which means repeating these results in actual patients would send the stock soaring.
I can't remember the last time a well-run company like Amgen shelled out significant sums for new drug candidates with so little information to base a decision on. Given the impressive preclinical results released so far, I really can't criticize the big biotech. That said, I'll be watching this company from a safe distance until there is a lot more data to work with.
